Self-Fixating Mesh Platform Helps Repair Hernias

The embedded adhesive, activated by tissue contact, was developed using a biomaterial production process that could also transform nearly any commercial mesh into a self-fixating mesh, thus facilitating greater clinical impact across a range of hernia types.

The proprietary adhesive platform works through rapid and biocompatible in situ cross-linking of structural proteins that mimics the biochemical cross-linking cascade of late stage blood coagulation. As the proteins cross-link, they undergo a process of gelation to form an adhesive hydrogel matrix. The result is a network similar to the fibrin network, but with an adhesive strength even greater than that of blood-derived fibrin sealants. The LifeMesh self-fixating hernia mesh is a product of LifeBond (Caesarea, Israel), and follows the company’s flagship product, LifeSeal surgical sealant.

“The successful expansion into a second, nondependent product platform is a great achievement for our company,” said Gideon Sturlesi, CEO of LifeBond. “Following clinical deployment of our first product, LifeSeal Surgical Sealant, LifeBond is now poised to rapidly realize additional products in our next-generation surgical toolbox pipeline.”

“LifeBond is at the forefront of a revolution to utilize biomaterial devices to integrate mechanical support with the body's natural tissue repair process,” said Orahn Preiss-Bloom, MSc, co-founder and COO of LifeBond. “We are excited that we have been able to translate our innovative technology into devices with great potential for patient benefit and look forward to continuing to grow our intellectual property portfolio.”

Related Links:
LifeBond